Skip to main content
OpenTrials
Completed

NCT Number: NCT05724797

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

This is a phase 1, first in human, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy adult male and female subjects 18 to 55 years of age, inclusive.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Frontage Clinical Research Center

Secaucus, New Jersey, 07094, United States

About this study

Subjects will provide written informed consent and undergo a screening visit within 28 days of receiving study drug. Eligible subjects must have a negative urine drug screen (UDS) and a negative naloxone challenge test at Screening and at the check-in visit (Day -1). Upon completion of screening, eligible subjects will be admitted to the clinical research unit (CRU) on Day -1 and remain confined in the CRU through completion of all scheduled procedures on Day 4 to allow for safety labs, pharmacokinetic (PK) blood draws, ECGs, injection site assessments, and adverse event monitoring.

Study medication dosing will occur in the morning on Day 1 and serial blood samples for plasma concentration determination for PK analysis will be taken during this time at pre-dose and 0.25, 0.50, 1, 1.5, 2, 4, 8, 10, 12, 24 (day 2), 48 (day 3), and 72 (day 4) hours post dose. Additional blood PK samples will be taken at follow-up visits. A Safety Review Committee (SRC) will review blinded, preliminary data from Cohort 1 to make recommendations regarding escalation to Cohorts 2 and 3.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female ≥18 and ≤55 years of age at time of consent
  • Body mass index ≥18.0 to ≤35.0 kg/m2
  • Medically healthy based on the absence of clinically significant abnormal vital sign
  • Females must have a negative serum pregnancy test at time of screening and negative urine pregnancy test upon admission; also, females of childbearing potential must agree to use a highly effective means of contraception from Screening until 9 months after receiving the study medication.
  • Male subjects with female partners of childbearing potential must agree to use a male condom and will be advised of the benefit for a female partner to use a highly effective method of contraception
  • Agree to stay within National Institute on Alcohol Abuse and Alcoholism (NIAAA) low risk drinking criteria. For women, low-risk drinking is no more than 3 drinks on any single day and no more than 7 drinks per week. For men, it is defined as no more than 4 drinks on any single day and no more than 14 drinks per week.
  • Agree not to take opioid analgesics.

Exclusion criteria

  • Clinically significant medical or psychiatric diagnosis (assessed on history, physical exam, ECG, and/or blood tests; includes significant history of cardiovascular, pulmonary, hepatic, gallbladder, or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, or active sexually transmitted disease).
  • Significant neuropsychiatric diagnosis (e.g., major depression, suicidal ideation, multiple sclerosis, dementia) as reported by the subject, or a past history of suicide attempt.
  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • History over last 30 days of consuming alcohol >3 drinks day per day or >7 drinks per week if female; if male >4 drinks per day or >14 drinks per week.
  • Currently uses tobacco or nicotine containing products, including but not limited to cigarettes, electronic cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum.
  • Reported history of a significant traumatic injury, major surgery, or open biopsy within the 4 weeks prior to signing the informed consent form.
  • Subject reported history of any use of long-term use of opioids agonists or antagonists; e.g., methadone, oxycodone, hydrocodone, naltrexone, buprenorphine.
  • Subject reported history of any medications to treat opioid use disorder (MOUD); e.g., methadone, naltrexone, buprenorphine, kratom.
  • Subject reports anticipated need for opioid analgesia in the next 12 months (e.g., planned surgery).
  • Subject reports history or presence of allergic or adverse response (including rash or anaphylaxis) to naloxone, naltrexone, nalmefene, morphinan opioid agonists, benzyl alcohol or sesame oil.
  • Positive urine drug screen (UDS) for barbiturates, benzodiazepines, cocaine, methamphetamine, or opioids.
  • Positive alcohol breath test.
  • Received an investigational drug within the last 30 days or 5 half-lives of the drug, whichever is longer, prior to administration of study medication.
  • Has taken exclusionary prohibited medications within the last 30 days or 5 half-lives of the drug, whichever is longer.
  • Subjects with a history of syncope, or have a history of symptomatic hypotension or symptomatic hypoglycemia.
  • Subjects who test positive for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HbsAg), or Hepatitis C virus (HCV) antibody.

Treatment and study plan

NRS-033

Drug

A single dose of NRS-033 will be administered

Placebo

Drug

A single dose of matching placebo will be administered

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Number of Participants with TEAEs

  2. Severity of TEAEs

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Severity of TEAEs

  3. Serious Adverse Events (SAEs)

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Number of Participants with SAEs

  4. Discontinuation Due to Adverse Events (AEs)

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Number of Participants who discontinue the study due to AEs

  5. Pharmacokinetics: AUC0-last

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Area under the plasma concentration-time curve (AUC) from time 0 to last measurable plasma concentration

  6. Pharmacokinetics: AUC0-infinity

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC0-last + AUCt-inf

  7. Pharmacokinetics: AUC0-inf %extrapolation

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Percentage of AUC0-inf due to extrapolation from Tlast to infinity

  8. Pharmacokinetics: Cmax

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Maximum observed plasma concentration (Cmax)

  9. Pharmacokinetics: Tmax

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Time of Cmax

  10. Pharmacokinetics: t1/2

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Terminal half-life (t1/2)

  11. Pharmacokinetics: Kel (λz)

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Apparent terminal rate-constant, calculated using linear regression on the terminal portion of the Log-concentration versus time curve

  12. Pharmacokinetics: Vz/F

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Apparent volume of distribution (Vz/F)

  13. Pharmacokinetics: CL/F

    Time frame: From predose through end of study visit, assessed up to study completion, an average of 15 months

    Apparent clearance (CL/F)

Sponsors and collaborators

Lead sponsor

Nirsum Labs

Industry

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

A Phase 1, First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of NRS 033 in Healthy Volunteers

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Feb 13, 2023
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.